Drug profile · INN
favipiravir
AVIGAN
favipiravir (AVIGAN) is a rna-directed rna polymerase inhibitor.
Drug details — favipiravir
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.78
Quick answer
favipiravir (AVIGAN) is a rna-directed rna polymerase inhibitor.
Key facts
Mechanism of action
RNA-directed RNA polymerase inhibitor
Primary target: RNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Recent coverage
EU secures emergency Favipiravir deliveries for hantavirus response
The European Commission said the EU has secured emergency deliveries of experimental Favipiravir for hantavirus, with first doses going to France, Spain and the Netherlands. The move appears aimed at strengthening preparedness and faster access if cases rise further.
Favipiravir Shipment to Europe Signals Hantavirus Preparedness Amidst Cruise Ship Outbreak
Experimental antiviral favipiravir has been shipped to Europe for hantavirus patients and clinical trials, marking a significant step in preparedness. Meanwhile, US passengers exposed to the virus are offered home quarantine with strict monitoring.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is favipiravir?
favipiravir (AVIGAN) is a rna-directed rna polymerase inhibitor.
What is the brand name for favipiravir?
AVIGAN is a marketed brand name for favipiravir. Check FDA Drugs@FDA for the current US label holder and prescribing information.